Treating cancers with immunotherapy and radiotherapy at the same time could stop them from becoming resistant to treatment, according to a study published in Cancer Research* today (Wednesday).
The researchers, based at The University of Manchester and funded by MedImmune, the global biologics research and development arm of AstraZeneca, and Cancer Research UK, found that combining the two treatments helped the immune system hunt down and destroy cancer cells that weren't killed by the initial radiotherapy in mice with breast, skin and bowel cancers.
Radiotherapy is a very successful treatment for many forms of cancer, but in cancer cells that it doesn't kill it can switch on a 'flag' on their surface, called PD-L1, that tricks the body's defences into thinking that cancerous cells pose no threat.
The immunotherapy works by blocking these 'flags' to reveal the true identity of cancer cells, allowing the immune system to see them for what they are and destroy them.
The approach improved survival and protected the mice against the disease from returning.
Dr Simon Dovedi, the lead researcher based at The University of Manchester and member of the Manchester Cancer Research Centre, said: "Using the body's own defences to treat cancers has huge potential with early phase clinical trials demonstrating exciting patient benefit but we are still at the early stages of understanding how best to use these types of treatments.
Combining certain immunotherapies with radiotherapy could make them even more effective and we're now looking to test this in clinical trial to see just how much of a difference it could make."
Professor Nic Jones, Cancer Research UK's chief clinician, said: "Around half of all cancer patients are given radiotherapy and it has been at the heart of helping improve survival rates so that today one in two cancer patients will survive for at least ten years. Doctors and researchers are constantly looking for ways to improve treatments and this approach could open the door to a whole new way of giving radiotherapy."
Dr Robert Wilkinson, Director of Oncology Research, MedImmune, said: "MedImmune is committed to developing strong science led collaborations, and supporting research that helps further advance our scientific understanding in the important area of immunotherapy. The findings described in the recent study with Cancer Research UK are extremely encouraging."
Cancer Research UK joined forces with The Christie NHS Foundation Trust and The University of Manchester to form the Manchester Cancer Research Centre allowing doctors and scientists to work closely together to turn scientific advances into patient benefits sooner.
Notes to editors:
*Dovedi, S.J., et al. Acquired resistance to fractionated radiation therapy can be overcome by concurrent PD-L1 blockade (2014) Cancer Research
Simon Shears | Eurek Alert!
Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Materials Sciences
06.12.2016 | Medical Engineering
06.12.2016 | Power and Electrical Engineering